Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines

Stem Cells

Volumn 15, Issue 2, 1997, Pages 94-103

  Mayordomo, Jose I ^a,b   Zorina, Tatiana ^a   Storkus, Walter J ^a   Zitvogel, Laurence ^a   Garcia Prats, Maria D ^a   Deleo, Albert B ^a   Lotze, Michael T ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Dendritic cells; Peptide vaccines; Tumor vaccines; Vaccine adjuvants

Indexed keywords

CANCER VACCINE;

ACTIVE IMMUNIZATION; ANTIGEN PRESENTATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG POTENTIATION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOGENICITY; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0030896205     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.150094     Document Type: Review

References (59)

1. Steinmann RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973;137:1142-1162.
2. Romani N, Schuler G. The immunologic properties of epidermal Langerhans cells as a part of the dendritic cell system. Semin Immunopathol 1992;13:265-279.
3. Kersall BL, Strober W. Distinct populations of dendritic cells are present in the subepithelial dome and T cell regions of the murine Peyer's patch. J Exp Med 1996;183:237-247.
4. Lu L, Woo J, Rao AS et al. Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med 1994;179:1823-1834.
5. Aager R, Crowley MT, Witmer-Pack MD. The surface of dendritic cells in the mouse as studied with monoclonal antibodies. Int Rev Immunol 1990;6:89-101.
6. Steinman RM, Inaba K. Stimulation of the primary mixed leukocyte reaction. CRC Crit Rev Immunol 1985;5:331-338.
7. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-296.
8. Caux C, Vanbervliet B, Massacrier C et al. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med 1994;180:1841-1847.
9. Inaba K, Witmer-Pack M, Inaba M et al. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 1994;180:1849-1860.
10. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-1118.
11. Koch F, Trockenbacher B, Schuler G et al. Antigen processing capacity of dendritic cells from mice of different MHC backgrounds: down-regulation upon culture and evidence for heterogeneity of dendritic cell populations. Adv Exp Med 1995;378:203-206.
12. + T immune responses induced by dendritic cells. Immunology 1995;85:467-474.
13. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58.
14. Koch F, Heufler C, Kampgen E et al. Tumor necrosis factor a maintains the viability of murine epidermal Langerhans cells in culture, but in contrast to granulocyte/macrophage colony-stimulating factor, without inducing their functional maturation. J Exp Med 1990;171:159-171.
15. Inaba K, Inaba M, Romani N et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693-1702.
16. Romani N, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
17. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNFα. J Exp Med 1996;184:695-706.
18. Zorina T, Mayordomo JI, Watkins S et al. Culture of dendritic cells from murine bone marrow supplemented with GM-CSF and TNF-alpha. J Immunother 1994;16:247.
19. Santiago-Schwarz F, Rappa DA, Laky K et al. Stem cell factor augments tumor necrosis factor-granulocyte-macrophage colony-stimulating factor-mediated dendritic cell hematopoiesis. STEM CELLS 1995;13:186-197.
20. Siena S, Di Nicola M, Mortarini R et al. Efficient ex vivo generation of functional dendritic cells (DCs) utilizable for tumor vaccination from blood cell transplants (BCT) in cancer patients. Proc Am Soc Clin Oncol 1996;15:554.
21. Shurin MR, Pandharipande PP, Sikora SS et al. Characterization of dendritic cells obtained from mice treated with flt3 ligand and IL-12. Fourth International Symposium on Dendritic Cells in Fundamental and Clinical Immunology. Venice (Italy), October 5-10, 1996.
22. Aichele P, Brduscha-Riem K, Zinkernagel RM et al. T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med 1995;182:261-266.
23. Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995;182:255-260.
24. Mizoguchi H, O'Shea JJ, Longo DL et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258:1795-1798.
25. Huang AYC, Golumbeck P, Ahmadzadeh M et al. The role of bone marrow-derived cells in presenting class I-restricted tumor antigens. Science 1994;264:961-965.
26. Zeid NA, Multer HK. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 1993;25:338-343.
27. Gallo O, Libonati GA, Gallina E et al. Langerhans cells related to prognosis in patients with laryngeal carcinoma. Arch Otorhinolaryngol 1991;117:1007-1010.
28. Giannini A, Bianchi S, Messerini L et al. Prognostic significance of accessory cells and lymphocytes in nasopharyngeal carcinoma. Pathol Res Pract 1991;187:496-502.
29. Becker Y. Dendritic cell activity against primary tumors: an overview. In Vivo 1993;7:187-191.
30. Qin Z, Noffz G, Mohaupt M et al. Interleukin 10 prevents dendritic cell infiltration and vaccination with granulocyte-macrophage-colony-stimulating-factor gene modified tumor cells. J Mol Med 1996;74:B9.
31. Grabbe S, Beissert S, Schwartz T et al. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today 1995;16:116-120.
32. Pardoll D. Tumour antigens: a new look for the 1990s. Nature 1994;369:357-358.
33. Storkus WJ, Lotze MT. Biology of tumor antigens: rumor antigens recognized by immune cells. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer, 2nd edition. Philadelphia: J.B. Lippincott Company, 1995:64-77.
34. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Medicine 1995;1:1297-1302.
35. Feltkamp MCW, Smits HL, Vierboom MP et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papilloma virus type 16-transformed cells. Eur J Immunol 1993;23:2242-2249.
36. Falo LD, Kovacsovics-Bankowski M, Thompson K et al. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nature Medicine 1995;1:649-653.
37. Mandelboim O, Berke G, Fridkin M et al. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 1994;369:67-71.
38. + T cells. Proc Natl Acad Sci USA 1994;91:3171-3175.
39. Mayordomo JI, Loftus DJ, Sakamoto H et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996;183:1357-1365.
40. Celluzzi C, Mayordomo JI, Storkus WJ et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-287.
41. Gyure LA, Barfoot R, Denham S et al. Immunity to a syngeneic sarcoma induced in rats by syngeneic lymph cells exposed to the tumour either in vivo or in vitro. Br J Cancer 1987;55:17-20.
42. Knight SC, Hunt R, Dore C et al. Influence of dendritic cells on tumor growth. Proc Natl Acad Sci USA 1985;82:4495-4497.
43. Caux C, Liu Y-L, Banchereau J. Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol Today 1995;16:2-4.
44. Grabbe S, Bruvers S, Gallo RL et al. Tumor antigen presentation by murine epidermal cells. J Immunol 1991;146:3656-3661.
45. Flamand V, Sornasse T, Thielemans K et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994;24:605-610.
46. + cytotoxic T lymphocytes. J Exp Med 1995;181:363-368.
47. Cox AL, Skipper J, Chen Y et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-719.
48. Storkus WJ, Zeh HJ III, Salter RD et al. Identification of T cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother 1993;14:94-103.
49. Zitvogel L, Mayordomo JI, Tjandrawan T et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 cosstimulation and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
50. Boczkowski D, Nair SK, Snyder D et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:465-472.
51. Bellone M, Iezzi G, Manfredi AA et al. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Eur J Immunol 1994;24:2691-2698.
52. Pan Z-K, Ikonomidis G, Lazenby A et al. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nature Medicine 1995;1:471-477.
53. Hsu FJ, Benike C, Fagnoni F et al. A clinical trial of antigen-pulsed dendritic cells in the treatment of patients with B-cell lymphoma. Proc Am Soc Clin Oncol 1996;15:419.
54. Kwak LW, Campbell MJ, Czerwinski DK et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992;327:1209-1215.
55. Storkus, WJ, Mayordomo JI, DeLeo A et al. Dendritic cells pulsed with tumor epitopes elicit potent antitumor CTL in vitro and in vivo. Meeting of the International Association of Immunology. 1995:3493a.
56. Bakker ABH, Mailand G, de Boer AJ et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 1995;55:5330-5334.
57. Koch F, Stanzl U, Jennewein P et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 1996;184:741-746.
58. Cella M, Scheidegger D, Palmer-Lehmann K et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996;184:747-752.
59. Storkus WJ, Mayordomo JI. Gene-modified dendritic cells as biologic adjuvants for cancer immunotherapy. J Mol Med 1996;74:B11.